ImmuneOncia (424870.KQ) stock: key figures, P/E, revenue and dividend
Health Care · South Korea
ImmuneOncia financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 654.54 m KRW | 111.21 m KRW |
| Gross profit | 654.54 m KRW | 111.21 m KRW |
| Operating income | -12.58 bn KRW | -28.01 bn KRW |
| EBIT | -5.68 bn KRW | -27.36 bn KRW |
| Net income | -5.69 bn KRW | -27.36 bn KRW |
| Diluted EPS – continuing operations | -72.36 KRW | -341.78 KRW |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About ImmuneOncia
ImmuneOncia Therapeutics, Inc., an immuno-oncology-centric biopharmaceutical company, develops immuno-oncology drugs for the treatment of cancer. It develops IMC-001, a human monoclonal antibody of the IgG1 type that targets PD-L1 an immunotherapy for cancer, which is in Phase II clinical trial for the treatment of NK/T cell lymphoma and solid cancer patients with high tumor mutation burden; and IMC-002, a human monoclonal antibody of the IgG4 type targeting human CD47, which is in Phase I a clinical trial for the treatment of solid cancers, such as triple-negative breast cancer, hepatocellular carcinoma, and bile duct cancer. The company also develops non clinical products, which includes IMC-201, a CD47xPD-L1 dual antibody based immunotherapy; and IMC-202, a PD-L1xTIGIT dual antibody based immunotherapy. The company was incorporated in 2016 and is headquartered in Yongin-si, South Korea. ImmuneOncia Therapeutics, Inc. operates as a subsidiary of Yuhan Corporation.
More stocks
- Wallix Group SA (ALLIX.PA)
- Ryde Group Ltd. (RYDE)
- ICTK Co., Ltd. (456010.KQ)
- KPX Chemical (025000.KS)
- ORAMED PHARMACEUTICALS INC. (ORMP)
- Pro-Hawk (8083.TWO)
- WZ Satu Berhad (7245.KL)
- Petronor E&P Ltd (PNOR.OL)
- Capitan Silver Corp. (CAPT.V)
- BaaS Innovation Co., Ltd. (3555.TWO)
- Golden Ventures Leasehold Real Estate Investment Trust (GVREIT.BK)
- Advance Materials Corporation (3585.TWO)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.